U2AF1 and myelodysplastic syndrome: Most MDS patients have at least one oncogenic mutation, with splicing factor mutations occurring in >50% of patients (Papaemmanuil et al., 2013), including SF3B1, SRSF2, U2AF1 and ZRSR2.